Arjun V. Balar

ScholarGPS® ID: 10327697629109

Highly Ranked Scholar - Prior Five Years:

Cisplatin

Affiliation

New York University, New York City, United States

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

137

Predicted Citations

6,021

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer (journal article) Loriot, Yohann \| Kalebasty, Arash Rezazadeh \| Fléchon, Aude \| Jain, Rohit K \| Gupta, Sumati \| Bupathi, Manojkumar \| Beuzeboc, Philippe \| Palmbos, Phillip \| Balar, Arjun V \| Kyriakopoulos, Christos E \| ... \| Tagawa, Scott T Future Oncology (2024). 10.2217/fon-2023-1030 Cite \| Source
A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1 (journal article) Agarwal, Neeraj \| Castellano, Daniel \| Alonso-Gordoa, Teresa \| Arranz Arija, Jose Angel \| Colomba, Emeline \| Gravis, Gwenaelle \| Mourey, Loic \| Oudard, Stephane \| Fléchon, Aude \| González, Macarena \| ... \| Piulats, José M. Clinical Cancer Research, volume 30, issue 11, pages 2377-2383 (2024). 10.1158/1078-0432.CCR-23-3436 Cite \| Source
HSR24-138: Real-World Treatment (tx) Patterns and Outcomes for First-Line (1L) Novel Hormonal Agent (NHA) Naïve Metastatic Castration Resistant Prostate Cancer (mCRPC) Including in Black and/or African American (BAA) Patients (Pts) (journal article) Smyth, Emily Nash \| Whipple, Samuel \| Guinter, Mark \| Haddad, Nadine \| Piao, Wenxian \| Cui, Zhanglin \| Balar, Arjun Journal of the National Comprehensive Cancer Network, volume 22, issue 2.5 (2024). 10.6004/jnccn.2023.7328 Cite \| Source
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes (journal article) Loriot, Y. \| Petrylak, D.P. \| Rezazadeh Kalebasty, A. \| Fléchon, A. \| Jain, R.K. \| Gupta, S. \| Bupathi, M. \| Beuzeboc, P. \| Palmbos, P. \| Balar, A.V. \| ... \| Tagawa, S.T. Annals of Oncology, volume 35, issue 4, pages 392-401 (2024). 10.1016/j.annonc.2024.01.002 Cited by (9) \| Cite \| Source
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting. (journal article) Nash Smyth, Emily \| Whipple, Samuel \| Guinter, Mark \| Haddad, Nadine \| Piao, Wenxian \| Cui, Zhanglin Lin \| Balar, Arjun Vasant Journal of Clinical Oncology, volume 42, issue 4_suppl, pages 55-55 (2024). 10.1200/JCO.2024.42.4_suppl.55 Cite \| Source
Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study. (journal article) Hollebecque, Antoine \| Kuboki, Yasutoshi \| Murciano-Goroff, Yonina R. \| Yaeger, Rona \| Cassier, Philippe Alexandre \| Heist, Rebecca Suk \| Fujiwara, Yutaka \| Deming, Dustin A. \| Ammakkanavar, Natraj \| Patnaik, Amita \| ... \| Koyama, Takafumi Journal of Clinical Oncology, volume 42, issue 3_suppl, pages 94-94 (2024). 10.1200/JCO.2024.42.3_suppl.94 Cited by (4) \| Cite \| Source
A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report (journal article) Bernstein, Ezra \| Weinberger, James \| Baskin, Avi \| Balar, Eesha \| Febles, Victor Adorno \| Balar, Arjun V. Current Problems in Cancer: Case Reports, volume 11 (2023). 10.1016/j.cpccr.2023.100252 Cite \| Source
Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). (journal article) Loriot, Yohann \| Petrylak, Daniel P. \| Rezazadeh, Arash \| Flechon, Aude \| Jain, Rohit K. \| Gupta, Sumati \| Bupathi, Manojkumar \| Beuzeboc, Philippe \| Palmbos, Phillip Lee \| Kyriakopoulos, Christos \| ... \| Tagawa, Scott T. Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 4514-4514 (2023). 10.1200/JCO.2023.41.16_suppl.4514 Cited by (1) \| Cite \| Source
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial (journal article) Economides, Minas P. \| Milowsky, Matthew I. \| O'Donnell, Peter H. \| Alva, Ajjai Shivaram \| Kollmeier, Marisa \| Rose, Tracy L \| Pitroda, Sean P. \| Rosenberg, Jonathan E. \| Hochman, Tsivia \| Goldberg, Judith D. \| ... \| Niglio, Scot Anthony Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 4509-4509 (2023). 10.1200/JCO.2023.41.16_suppl.4509 Cited by (2) \| Cite \| Source
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial (journal article) Larkin, James \| Oya, Mototsugu \| Martignoni, Marcella \| Thistlethwaite, Fiona \| Nathan, Paul \| Ornstein, Moshe C \| Powles, Thomas \| Beckermann, Kathryn E \| Balar, Arjun V \| McDermott, David \| ... \| Choueiri, Toni K The Oncologist, volume 28, issue 4, pages 333-340 (2023). 10.1093/oncolo/oyac243 Cited by (3) \| Cite \| Source
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. (journal article) Petrylak, Daniel P. \| Tagawa, Scott T. \| Jain, Rohit K. \| Bupathi, Manojkumar \| Balar, Arjun V. \| Rezazadeh, Arash \| George, Saby \| Palmbos, Phillip Lee \| Nordquist, Luke T. \| Davis, Nancy B. \| ... \| Grivas, Petros Journal of Clinical Oncology, volume 41, issue 6_suppl, pages 520-520 (2023). 10.1200/JCO.2023.41.6_suppl.520 Cited by (14) \| Cite \| Source
Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). (journal article) Tagawa, Scott T. \| Balar, Arjun V. \| Petrylak, Daniel P. \| Rezazadeh, Arash \| Loriot, Yohann \| Flechon, Aude \| Jain, Rohit K. \| Agarwal, Neeraj \| Bupathi, Manojkumar \| Barthelemy, Philippe \| ... \| Grivas, Petros Journal of Clinical Oncology, volume 41, issue 6_suppl, pages 526-526 (2023). 10.1200/JCO.2023.41.6_suppl.526 Cited by (11) \| Cite \| Source
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02 (journal article) Siefker-Radtke, Arlene O. \| Cho, Daniel C. \| Diab, Adi \| Sznol, Mario \| Bilen, Mehmet A. \| Balar, Arjun V. \| Grignani, Giovanni \| Puente, Erika \| Tang, Lily \| Chien, David \| ... \| Tannir, Nizar M. European Urology, volume 82, issue 4, pages 365-373 (2022). 10.1016/j.eururo.2022.05.002 Cited by (10) \| Cite \| Source
1423TiP CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) (journal article) McKay, R.R. \| Agarwal, N. \| Matsubara, N. \| Piulats Rodriguez, J.M. \| Smith, M.R. \| Todenhöfer, T. \| Zhang, T. \| Balar, A.V. \| Schaverien, C. \| Sherwood, S. \| ... \| Sweeney, C.J. Annals of Oncology, volume 33 (2022). 10.1016/j.annonc.2022.07.1909 Cited by (1) \| Cite \| Source
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial (journal article) McGregor, Bradley \| O'Donnell, Peter H. \| Balar, Arjun \| Petrylak, Daniel \| Rosenberg, Jonathan \| Yu, Evan Y. \| Quinn, David I. \| Heath, Elisabeth I. \| Campbell, Mary \| Hepp, Zsolt \| ... \| Galsky, Matthew D. European Urology, volume 81, issue 5, pages 515-522 (2022). 10.1016/j.eururo.2022.01.032 Cited by (16) \| Cite \| Source
Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States (journal article) Wu, Jennifer \| Yakubov, Amin \| Abdul-Hay, Maher \| Love, Erica \| Kroening, Gianna \| Cohen, Deirdre \| Spalink, Christy \| Joshi, Ankeeta \| Balar, Arjun \| Joseph, Kathie-Ann \| ... \| Mehnert, Janice JCO Oncology Practice, volume 18, issue 4, pages e620-e625 (2022). 10.1200/OP.21.00629 Cited by (3) \| Cite \| Source
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study (journal article) Tannir, Nizar M \| Cho, Daniel C \| Diab, Adi \| Sznol, Mario \| Bilen, Mehmet A \| Balar, Arjun V \| Grignani, Giovanni \| Puente, Erika \| Tang, Lily \| Chien, David \| ... \| Hurwitz, Michael E Journal for ImmunoTherapy of Cancer, volume 10, issue 4, pages e004419- (2022). 10.1136/jitc-2021-004419 Cited by (14) \| Cite \| Source
Germline APC (I1307K) mutation and clinical outcomes in prostate cancer. (journal article) Economides, Minas P. \| Nakazawa, Mari \| Lee, Jonathan \| Hollifield, Lucas \| Balar, Arjun Vasant \| Antonarakis, Emmanuel S. \| Wise, David R Journal of Clinical Oncology, volume 40, issue 6_suppl, pages 144-144 (2022). 10.1200/JCO.2022.40.6_suppl.144 Cite \| Source
First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. (journal article) Loriot, Yohann \| Grivas, Petros \| De Wit, Ronald \| Balar, Arjun Vasant \| Siefker-Radtke, Arlene O. \| Zolnierek, Jakub \| Csoszi, Tibor \| Shin, Sang Joon \| Park, Se Hoon \| Atduev, Vagif \| ... \| Matsubara, Nobuaki Journal of Clinical Oncology, volume 40, issue 6_suppl, pages 432-432 (2022). 10.1200/JCO.2022.40.6_suppl.432 Cited by (17) \| Cite \| Source
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy (journal article) Autio, Karen A. \| Antonarakis, Emmanuel S. \| Mayer, Tina M. \| Shevrin, Daniel H. \| Stein, Mark N. \| Vaishampayan, Ulka N. \| Morris, Michael J. \| Slovin, Susan F. \| Heath, Elisabeth I. \| Tagawa, Scott T. \| ... \| Scher, Howard I. European Urology Open Science, volume 34 (2021). 10.1016/j.euros.2021.09.015 Cited by (6) \| Cite \| Source